Actelion (Actelion) Change In Receivables : $-25 Mil (TTM As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Change In Receivables?

Actelion's change in receivables for the quarter that ended in Mar. 2017 was $-38 Mil. It means Actelion's Accounts Receivable increased by $38 Mil from Dec. 2016 to Mar. 2017 .

Actelion's change in receivables for the fiscal year that ended in Dec. 2016 was $-12 Mil. It means Actelion's Accounts Receivable increased by $12 Mil from Dec. 2015 to Dec. 2016 .

Actelion's Accounts Receivable for the quarter that ended in Mar. 2017 was $0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Actelion's Days Sales Outstanding for the three months ended in Mar. 2017 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Actelion's liquidation value for the three months ended in Mar. 2017 was $98 Mil.

Actelion Change In Receivables Historical Data

The historical data trend for Actelion's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Change In Receivables Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Receivables

Get a 7-Day Free Trial

119.56

-10.49

10.21

-31.53

-12.20

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Change In Receivables	Get a 7-Day Free Trial															-27.41	16.32	-49.45	45.87	-38.15

Actelion Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25 Mil.

Actelion (OTCPK:ALIOF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Actelion's Days Sales Outstanding for the quarter that ended in Mar. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	645.285	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Actelion's accounts receivable are only considered to be worth 75% of book value:

Actelion's liquidation value for the quarter that ended in Mar. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	758.638	-	726.38	+	0.75 * 0	+	0.5 * 132.372
=	98

Actelion Change In Receivables Related Terms

Thank you for viewing the detailed overview of Actelion's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016